EVP Chief Commercial Officer of Dexcom Inc (30-Year Financial, Insider Trades) Richard Doubleday (insider trades) sold 1,531 shares of DXCM on 06/23/2020 at an average price of $409.41 a share. The total sale was $626,807.
DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. DexCom Inc has a market cap of $37.54 billion; its shares were traded at around $398.09 with a P/E ratio of 250.38 and P/S ratio of 23.04. GuruFocus has detected 3 severe warning signs with DexCom Inc. .
CEO Recent Trades:
- President, CEO and Chairman Kevin R Sayer sold 6,000 shares of DXCM stock on 06/01/2020 at the average price of $376.57. The price of the stock has increased by 5.71% since.
Directors and Officers Recent Trades:
- EVP Strategy and Corporate Dev Steven Robert Pacelli sold 1,531 shares of DXCM stock on 06/23/2020 at the average price of $409.37. The price of the stock has decreased by 2.76% since.
- EVP Chief Commercial Officer Richard Doubleday sold 1,531 shares of DXCM stock on 06/23/2020 at the average price of $409.41. The price of the stock has decreased by 2.76% since.
- * Andrew K Balo sold 6,522 shares of DXCM stock on 06/15/2020 at the average price of $366.47. The price of the stock has increased by 8.63% since.
- Director Nicholas Augustinos sold 1,875 shares of DXCM stock on 06/15/2020 at the average price of $366.65. The price of the stock has increased by 8.57% since.
- EVP Chief Technology Officer Jacob Steven Leach sold 19,129 shares of DXCM stock on 06/11/2020 at the average price of $376.76. The price of the stock has increased by 5.66% since.
For the complete insider trading history of DXCM, click here
.
